Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review

Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review

Yonghui Wu,1,* Kai Zhang,1,* Jiexia Guan,2 Weibin Wu,1 Jian Zhang,1 Huiguo Chen1 1Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, 510630, People’s Republic of China; 2Department of Pathology, The Third Affiliated Hospital...

Full description

Bibliographic Details
Main Authors: Wu Y, Zhang K, Guan J, Wu W, Zhang J, Chen H
Format: Article
Language:English
Published: Dove Medical Press 2021-09-01
Series:Cancer Management and Research
Subjects:
egfr mutation
pik3ca mutation
resistant mutation
adenosquamous carcinoma
anlotinib
Online Access:https://www.dovepress.com/treatment-with-anlotinib-after-chemotherapy-and-egfr-tki-resistance-in-peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/treatment-with-anlotinib-after-chemotherapy-and-egfr-tki-resistance-in-peer-reviewed-fulltext-article-CMAR

Similar Items